156 related articles for article (PubMed ID: 36284648)
1. Anti-tumor effects of perampanel in malignant glioma cells.
Tatsuoka J; Sano E; Hanashima Y; Yagi C; Yamamuro S; Sumi K; Hara H; Takada K; Kanemaru K; Komine-Aizawa S; Katayama Y; Yoshino A
Oncol Lett; 2022 Dec; 24(6):421. PubMed ID: 36284648
[TBL] [Abstract][Full Text] [Related]
2. Anti‑tumor effects of anti‑epileptic drugs in malignant glioma cells.
Yagi C; Tatsuoka J; Sano E; Hanashima Y; Ozawa Y; Yoshimura S; Yamamuro S; Sumi K; Hara H; Katayama Y; Yoshino A
Oncol Rep; 2022 Dec; 48(6):. PubMed ID: 36281939
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
4. Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines.
Salmaggi A; Corno C; Maschio M; Donzelli S; D'Urso A; Perego P; Ciusani E
J Pers Med; 2021 May; 11(5):. PubMed ID: 34068749
[TBL] [Abstract][Full Text] [Related]
5. AMPA receptor antagonist perampanel affects glioblastoma cell growth and glutamate release in vitro.
Lange F; Weßlau K; Porath K; Hörnschemeyer MF; Bergner C; Krause BJ; Mullins CS; Linnebacher M; Köhling R; Kirschstein T
PLoS One; 2019; 14(2):e0211644. PubMed ID: 30716120
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ribavirin against malignant glioma cell lines.
Ogino A; Sano E; Ochiai Y; Yamamuro S; Tashiro S; Yachi K; Ohta T; Fukushima T; Okamoto Y; Tsumoto K; Ueda T; Yoshino A; Katayama Y
Oncol Lett; 2014 Dec; 8(6):2469-2474. PubMed ID: 25364409
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effect of lenalidomide in malignant glioma cell lines.
Hanashima Y; Sano E; Sumi K; Ozawa Y; Yagi C; Tatsuoka J; Yoshimura S; Yamamuro S; Ueda T; Nakayama T; Hara H; Yoshino A
Oncol Rep; 2020 May; 43(5):1580-1590. PubMed ID: 32323826
[TBL] [Abstract][Full Text] [Related]
8. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
[TBL] [Abstract][Full Text] [Related]
10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
11. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
Heuer S; Burghaus I; Gose M; Kessler T; Sahm F; Vollmuth P; Venkataramani V; Hoffmann D; Schlesner M; Ratliff M; Hopf C; Herrlinger U; Ricklefs F; Bendszus M; Krieg SM; Wick A; Wick W; Winkler F
BMC Cancer; 2024 Jan; 24(1):135. PubMed ID: 38279087
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase 1 is highly expressed in glioma stem cells.
Ozawa Y; Yamamuro S; Sano E; Tatsuoka J; Hanashima Y; Yoshimura S; Sumi K; Hara H; Nakayama T; Suzuki Y; Yoshino A
Biochem Biophys Res Commun; 2020 Apr; 524(3):723-729. PubMed ID: 32035622
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide.
Kanzawa T; Germano IM; Kondo Y; Ito H; Kyo S; Kondo S
Br J Cancer; 2003 Sep; 89(5):922-9. PubMed ID: 12942127
[TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase.
Fukai J; Koizumi F; Nakao N
PLoS One; 2014; 9(8):e104538. PubMed ID: 25111384
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of ribavirin against malignant glioma cell lines: Follow-up study.
Ochiai Y; Sano E; Okamoto Y; Yoshimura S; Makita K; Yamamuro S; Ohta T; Ogino A; Tadakuma H; Ueda T; Nakayama T; Hara H; Yoshino A; Katayama Y
Oncol Rep; 2018 Feb; 39(2):537-544. PubMed ID: 29251333
[TBL] [Abstract][Full Text] [Related]
18. Apcin inhibits the growth and invasion of glioblastoma cells and improves glioma sensitivity to temozolomide.
Ding Y; Zhang C; He L; Song X; Zheng C; Pan Y; Yu S
Bioengineered; 2021 Dec; 12(2):10791-10798. PubMed ID: 34753395
[TBL] [Abstract][Full Text] [Related]
19. Combination Therapy with AKT3 and PI3KCA siRNA Enhances the Antitumor Effect of Temozolomide and Carmustine in T98G Glioblastoma Multiforme Cells.
Paul-Samojedny M; Pudełko A; Kowalczyk M; Fila-Daniłow A; Suchanek-Raif R; Borkowska P; Kowalski J
BioDrugs; 2016 Apr; 30(2):129-44. PubMed ID: 26902608
[TBL] [Abstract][Full Text] [Related]
20. Combination of levetiracetam and IFN-α increased temozolomide efficacy in MGMT-positive glioma.
Ni XR; Guo CC; Yu YJ; Yu ZH; Cai HP; Wu WC; Ma JX; Chen FR; Wang J; Chen ZP
Cancer Chemother Pharmacol; 2020 Dec; 86(6):773-782. PubMed ID: 33074386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
